Word: squibb
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
Here’s a little example: Back in the 1980s, a researcher at Yale discovered a compound which looked to be a promising new drug to fight the AIDS virus. Yale, in turn, licensed the compound to Bristol Myers Squibb (BMS), a British pharmaceutical corporation. BMS proceeded to develop the drug, later named d4T, and to patent it in several countries, including South Africa...
...hundreds of millions of dollars it has paid out to treat injuries the agency says were caused by the products. That effort took a big step forward two weeks ago when a federal appeals court in Atlanta, reversing a lower court, said the government?s suit against Bristol Myers Squibb, Baxter International, 3M, Union Carbide and Union Carbide Chemical and Plastics, could proceed...
...their legal problems, I have looked at pharma. I still cannot help but look at the demographics in Europe, Japan and the U.S., which says we're going to be eating many, many more pills. The growth potential there is misunderstood. I like Pfizer, Merck, GlaxoSmithKline, Bristol-Myers Squibb...
...drive sales or earnings." Turning the corner on profits is more critical than ever, because large drug companies have tired of taking big risks in biotech and tend to shun early-stage research in favor of safer investments in drugs near approval or already approved. Bristol-Myers Squibb made a disastrous $2 billion investment in 2001 in ImClone Systems, which suffered costly setbacks with its cancer drug Erbitux before a breakthrough this spring. With Big Pharma playing it safe, steady-earning biotech leaders are the ones with the wherewithal - and the disposition - to partner with cash-strapped firms developing promising...
...global health-care investment group. Turning the corner on profits is more critical than ever, because large drug companies have tired of taking big risks in biotech and tend to shun early-stage research in favor of safer investments in drugs near approval or already approved. Bristol-Myers Squibb made a disastrous $2 billion investment in 2001 in ImClone Systems, which suffered costly setbacks with its cancer drug Erbitux before that drug had a breakthrough this spring. With Big Pharma playing it safe, steady-earning biotech leaders are the ones with the wherewithal--and the disposition--to partner with cash...